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Background: Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around
disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid
profiles.
Methods: We compared changes in lipid profiles in a population based incident cohort of 689 patients with
psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/
index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine
trends in lipid profiles.
Results: There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the
5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a
greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density
lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort.
Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients
with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering
drugs between the two cohorts.
Conclusions: Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before
psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis
incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further
exploration.
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Psoriasis is becoming understood as a systemic and in-
flammatory disease with increased associated comorbid-
ities, including risk for cardiovascular (CV) disease [1,2].
Among the comorbidities which predispose patients
with psoriasis to increased risk of CV disease are psori-
atic arthritis and sleep disorders [3], as well as other
traditional risk factors for CV disease, including athero-
genic lipid profiles [4,5].* Correspondence: crowson@mayo.edu
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distribution, and reproduction in any mediumLittle is known about the impact of psoriasis on lipids
in patients with new onset psoriasis. A number of stud-
ies have demonstrated a pro-atherogenic lipid profile in
psoriasis, but not all [5-9]. There is now growing evi-
dence that psoriasis is associated with enhanced athero-
sclerosis and unfavorable lipid profiles, but some of the
conflicting results examining this relationship may be at
least in part influenced by the effects of inflammation
related to psoriasis, as well as its treatment [6].
To address the relationship between psoriasis and the
profile of potentially atherogenic lipids, we performed a
longitudinal study of changes in lipid profile during the
period surrounding psoriasis incidence in a population-
based cohort of patients with psoriasis and a comparison
cohort of non-psoriasis subjects. The aim of this studyentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lipid profiles by comparing lipid profiles in patients with
psoriasis and non-psoriasis subjects during the 5 years
before and 5 years after psoriasis incidence/index date.
Methods
This retrospective longitudinal cohort study was per-
formed using the population-based resources of the
Rochester Epidemiology Project (REP) medical records
linkage system. This records linkage system allows ready
access to the complete medical records from all health
care providers from the Mayo Clinic and its affiliated
hospitals, the Olmsted Medical Center, the Olmsted
Community Hospital, local nursing homes, and the few
private practitioners. The potential of this data system
for population-based studies has been described else-
where [10-12]. This system ensures virtually complete
ascertainment of all clinically recognized cases of psoria-
sis among the residents of Olmsted County, MN.
The study population comprised a retrospectively
identified incidence cohort of Olmsted County, MN resi-
dents ≥35 years of age who were first diagnosed with
psoriasis between January 1, 1988 and January 1, 2008,
and have at least one lipid measure during the time
period from 5 years before to 5 years after psoriasis inci-
dence date. The complete medical records of all subjects
were reviewed, and psoriasis was validated by either a
confirmatory diagnosis in the medical record by a
dermatologist, or a physician’s description of the lesions
in the medical record or a skin biopsy, whenever avail-
able. For the majority of psoriasis subjects (551/689 =
80%), data was also collected on start and stop dates of
all courses of systemic drug therapy, including metho-
trexate (MTX), oral retinoids, azathioprine, cyclosporine,
hydroxychloroquine, sulfasalazine, leflunomide, and bio-
logics (i.e., etanercept, infliximab, adalimumab, golimu-
mab, efalizumab, alefacept).
In case of a doubtful diagnosis, the medical record was
reviewed by the dermatologist co-investigator. Incidence
date was defined as the physician diagnosis date. Sub-
jects with prevalent psoriasis, subjects with missing
medical records, and those who denied research
authorization were excluded.
For each patient with psoriasis, a non-psoriasis subject
of similar age, sex, calendar year and length of medical
history prior to index date was randomly selected from
the same population. Each non-psoriasis subject was
assigned an index date corresponding to the psoriasis in-
cidence date of the corresponding patient with psoriasis.
All lipid measures performed for clinical indications
from 5 years prior to psoriasis incidence/index date to
last follow-up were abstracted. These included total
cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL) and triglycerides [TG]). Inaccordance with Adult Treatment Panel III (ATPIII)
guidelines [13], abnormal lipid levels were defined as TC
≥240 mg/dL, LDL ≥160 mg/dL, TG ≥200 mg/dL or HDL
<40 mg/dL. Data on prescription of lipid-lowering medi-
cations (i.e., statins and other lipid-lowering drugs) and
body mass index were also collected. Obesity was
defined as body mass index ≥ 30 kg/m2. The study
protocol was approved by the Institutional Review
Boards from Mayo Clinic and Olmsted Medical Center.
Statistical methods
Descriptive statistics (means, percentages, etc.) were
used to summarize the lipid measures. Demographics of
patients with psoriasis and non-psoriasis subjects, as
well as subjects with and without lipid measures, were
compared using Chi-square tests and t-tests. Random
effects models adjusting for age, sex, and calendar year
of psoriasis incidence/index date were used to analyze
the trends in lipid profiles during the time period from 5
years before to 5 years after psoriasis incidence/index
date. These models accounted for multiple measure-
ments per subject using random effects to fit individual
intercepts and slopes for each subject. Generalized addi-
tive models with smoothing splines were used to illus-
trate the trends in lipid levels over time.
Results
A total of 963 Olmsted County, MN residents aged ≥35
years were diagnosed with psoriasis between 1/1/1988
and 1/1/2008. Of these, 689 patients had at least one
lipid measure during the time period from 5 years before
to 5 years after psoriasis incidence date and thus were
included in the study (Table 1). The total number of
lipid measurements in patients with psoriasis was 3,561
(median 3 measurements per patient). Patients with
psoriasis without lipid measures during the time period
of interest (n=274) were younger (mean age 51.9 years,
p<0.001) and were more likely to be male (59.5% vs.
46.2%) than patients with psoriasis in whom lipid mea-
sures were obtained. Within the same time period, lipid
measurements were also available for 717 non-psoriasis
subjects with a total of 3,678 lipid measurements (me-
dian 3 measurements per subject). The spread of mea-
surements were similar for both groups (mean 9.38
years, standard deviation (SD) 1.36 years for psoriasis
and mean 9.32 years, SD 1.45 years for non-psoriasis
(p=0.68). Non-psoriasis subjects had similar age and sex
characteristics compared to patients with psoriasis with
lipid measures. In addition, the prevalence of lipid-
lowering drug use was similar among psoriasis and non-
psoriasis subjects (37% vs. 39%, respectively; p=0.33).
Data on systemic medication used was available in 551
of the 689 psoriasis subjects. Of these, 49 (8.9% of the
551) used systemic medication during the study period.





Age at psoriasis incidence/index date (years), mean (±Standard Deviation) 55.2 (± 13.2) 55.6 (± 13.3)
Male, No. (%) 353 (49) 318 (46)
Observation time (years)
Before incidence/index date, mean (median) 4.73 (5) 4.71 (5)
After incidence/index date, mean (median) 4.65 (5) 4.61 (5)
Lab measurements
Total number 3678 3561
Number per subject before incidence/index date, mean (median) 2.1 (1) 2.0 (1)
Number per subject after incidence/index date, mean (median) 3.0 (2) 3.2 (2)
Use of statins and/or lipid lowering therapy, No. (%) 262 (37) 269 (39)
Obesity* 301 (46) 271 (39)
*Body mass index at psoriasis incidence or non-psoriasis index date was available in 660 psoriasis and 693 non-psoriasis subjects.
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were similar in both psoriasis and non-psoriasis subjects
(Table 1). The median follow-up was 5 years in each co-
hort as the follow-up was truncated at 5 years for these
analyses. A full 5 years of follow-up after psoriasis inci-
dence/index date was available for 533 (77%) of patients
with psoriasis and 563 (79%) of non-psoriasis subjects.
In addition, 628 (91%) of psoriasis and 650 (91%) of
non-psoriasis subjects had 5 years of available informa-
tion prior to psoriasis incidence/index date. The mean
time prior to psoriasis incidence/index date was 4.7
years in both groups with a median of 5 years.
Table 2 shows the mean difference in lipid levels be-
tween the psoriasis and non-psoriasis cohorts adjusted
for age, and calendar year. Overall, TG levels were sig-
nificantly higher in psoriasis compared to non-psoriasis
subjects (on average 16.8 mg/dL; p<0.001) and HDL
levels were significantly lower in patients with psoriasis
compared to non-psoriasis subjects (−1.9 mg/dL;
p=0.013). Subgroup analyses were performed for males
and females, and non-obese and obese subjects, as well
as statin users. Differences in TG levels between psoria-
sis and non-psoriasis subjects were more pronouncedTable 2 Mean differences in lipid levels in psoriasis patients c
statin use
Lipid measure Overall Sex
Female Ma
Total Cholesterol (TC) 0.6 3.0 −1
Low-density Lipoprotein −0.9 −1.3 −0
High-density Lipoprotein (HDL) −1.9* 2.2* −6
Triglycerides 16.8* 8.6 25
TC: HDL ratio 0.2* −0.1 0
* p<0.05, indicates significant difference in mean lipid levels between psoriasis and
mean differences in psoriasis minus non-psoriasis cohorts in mg/dL.among males, obese subjects and statin users, and less
pronounced among females, non-obese patients and
those who did not use statins. No difference in mean
lipid levels of TC or LDL between psoriasis and non-
psoriasis subjects were noted overall or in any subgroups
of patients.
Figure 1 and Table 3 show the trends in lipids during
the 5 years before and 5 years after psoriasis incidence/
index date in the psoriasis and non-psoriasis cohorts.
There were significant declines in TC and LDL levels
during the 5 years before and the 5 years after psoriasis
incidence/index date in both the psoriasis and the non-
psoriasis cohort. HDL levels increased significantly both
before and after psoriasis incidence date in the psoriasis
cohort. There was no significant change in HDL during
the 5 years before index date in the non-psoriasis cohort.
Subgroup analyses were performed for statin users.
Statin users experienced significant declines in TC
and LDL in both the psoriasis and non-psoriasis
cohorts, as expected. However, there were no differ-
ences in the trends in lipids between the psoriasis
and non-psoriasis groups among the subgroup of
patients taking statins.ompared to non-psoriasis subjects according to sex and
Obesity Statin use
le Non-obese Obese Non-user User
.8 0.1 0.4 0.4 3.4
.2 0.1 −2.3 −1.1 −0.7
.1* −1.7 −1.1 −2.1* −1.3
.2* 7.6 21.4* 17.7* 29.4*
.5* 0.2* 0.1 0.2* 0.2
non-psoriasis cohorts adjusted for age and calendar year. Values in table are
Figure 1 Trends in lipid levels in psoriasis patients (solid lines) and non-psoriasis subjects (dashed lines) during the time period from 5
years before to 5 years after psoriasis incidence/index date adjusting for age, sex and calendar year of psoriasis diagnosis.
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Both psoriasis and dyslipidemia are risk factors for car-
diovascular disease in patients with psoriasis. To exam-
ine this relationship, we performed this retrospective
study of lipid profiles during the period surrounding
psoriasis incidence in a population-based cohort of
patients with psoriasis and a comparison cohort of non-
psoriasis subjects. There were significant declines in TC
and LDL levels during the 5 years before and the 5 years
after psoriasis incidence/index date in both the psoriasis
and the non-psoriasis cohorts with a greater decreaseTable 3 Mean changes in lipid levels in psoriasis patients and
after psoriasis incidence/index date based on random effects
Lipid measure Five-year change before the
incidence/index dat
Psoriasis No
Total Cholesterol (TC) −6.2 (−11.7, -0.7)* −15
Low-density Lipoprotein −8.3 (−13.0, -3.6) −14
High-density Lipoprotein (HDL) 2.1 (0.8, 3.4) 1
Triglycerides 1.6 (−13.5, 16.6) −7
TC: HDL ratio −0.3 (−0.4, -0.1) −0
* (p=0.024) indicates difference between the trends in lipid changes between psori
intervals.noted in the TC levels and LDL in the non-psoriasis co-
hort. HDL levels increased significantly both before and
after psoriasis incidence in the psoriasis cohort, but sig-
nificant increases were seen only in the 5 years after
index date for the non-psoriasis cohort. TG levels
showed an increase in the 5 year period before psoriasis
incidence in the psoriasis cohort and a decline prior to
index date in the non-psoriasis cohort, but they did not
achieve statistical significance. Lipid trends during the 5
years after incidence/index date were largely similar in




Five-year change after the psoriasis
incidence/index date
n-psoriasis Psoriasis Non-psoriasis
.3 (−20.7, -9.9) −15.9 (−20.3, -11.4) −13.6 (−17.8, -9.5)
.2 (−19.2, -9.2) −13.2 (−17.1, -9.2) −13.2 (−16.8, -9.5)
.2 (−0.1, 2.6) 1.4 (0.2, 2.5) 1.7 (0.6, 2.9)
.0 (−18.0, 4.0) −20.2 (−31.3, -9.0) −15.8 (−24.5, -7.2)
.4 (−0.6, -0.2) −0.5 (−0.7, -0.4) −0.5 (−0.6, -0.3)
asis and non-psoriasis cohorts. Values in parentheses are 95% confidence
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tween the trends in both groups.
There is conflicting information about how lipid pro-
files might be affected by psoriasis. An atherogenic lipid
profile namely, higher cholesterol, LDL and TG levels
were noted in psoriasis patients in some studies [5,7],
with no significant difference between patients and con-
trols noted in others [7-9]. It is also unknown whether
the observed lipid changes are primary or secondary to
the chronic inflammatory process or its treatment [6,14].
We sought to examine the potential relationship of
psoriasis and dyslipidemia by examining lipid profiles in
patients around the time of psoriasis onset. As far as we
can ascertain, this is the first population-based study to
describe longitudinal lipid trends in psoriasis and non-
psoriasis populations both before and after psoriasis in-
cidence/index date. The data from our study show that
although there is indeed a downward trend in TC and
LDL in both populations in the five years before psoria-
sis incidence/index date, the decline in TC and LDL
levels was smaller in the psoriasis patients than in the
non-psoriasis subjects. This atherogenic trend in the
psoriasis subjects is further demonstrated by significantly
increased TG levels and significantly lower HDL levels
in psoriasis subjects compared to non-psoriasis subjects
over the duration of the study.
There is an emerging consensus as to the role of the
chronic inflammatory state in diseases like systemic lupus
erythematosus and rheumatoid arthritis and the accom-
panying proinflammatory milieu in promoting develop-
ment and progression of dyslipidemia and atherosclerosis.
It is likely that psoriasis, a chronic immune mediated in-
flammatory skin disease, may predispose individuals to
dyslipidemia [15]. This association is demonstrably stron-
ger for severe psoriasis and psoriatic arthritis [5,15]. Psoria-
sis has also been shown to be an independent risk factor
for cardiovascular mortality [16,17]. In addition, there
appears to be a significant association between psoriasis
and traditional risk factors for atherosclerosis and heart
disease in the general population such as diabetes mellitus
type II, coronary artery disease, peripheral vascular disease
and hypertensive heart disease [13,15,16,18,19].
In our study, patients with psoriasis tended to have a
smaller decline in the TC and LDL levels compared to
non-psoriasis subjects in the 5 years before psoriasis in-
cidence/index date, a finding which is concordant with
some previous studies [5-7]. Direct comparisons with
these findings cannot be made due to the differences in
study design, time periods and populations involved.
The downward trend in TC and LDL prior to psoriasis
incidence is not without precedent and has also been
demonstrated in other chronic inflammatory conditions
such as rheumatoid arthritis [20]. The apparent paradox
of downward trending total cholesterol levels andincreased cardiovascular mortality risk in psoriasis may
be explained by the altered cytokine milieu [16,19,21,22]
and inflammation [23]. This is also consistent with the
lowering of the plasma cholesterol concentrations seen
in chronic inflammatory conditions [24,25].
The lowering of TC and LDL in the 5 years prior to
psoriasis incidence was unlikely to have been caused by
treatment for psoriasis. The broad downward trend in
lipids in both the patients with psoriasis and the com-
parator subjects who did not have psoriasis could be
partly explained by the increasing usage of lipid-
lowering drugs in the general population during time
period covered by the study [26]. A similar explanation
might be suggested for the changes in HDL. However,
the changes probably cannot be attributed solely to lipid
lowering medications, as there was no difference in the
number of subjects on lipid lowering medications in ei-
ther cohort. An effect of onset of psoriasis contributing
to the less marked decline in TC and LDL, with signifi-
cantly higher TG and lower HDL, compared to non-
psoriasis subjects cannot be excluded.
Strengths of this study include the longitudinal popula-
tion based study design using the data from the Roches-
ter Epidemiology Project with comprehensive data
collection of the target population. We analyzed lipid
trends before and after the incidence of psoriasis to as-
certain longitudinal trends in these subjects. It is possible
that patients with psoriasis had greater provider contact
leading to greater number of lipid measurements and
interventions. However, no differences in the number of
lipid measures per person in patients with and without
psoriasis were noted, and multiple measurements per
person were accounted for during statistical analysis.
The population of Olmsted County, Minnesota is pre-
dominantly white, so that results may not be genera-
lizable to non-white subjects. Except for the higher
proportion of the population with higher educational
levels, other sociodemographic characteristics of Olmsted
County, Minnesota residents are similar to those of US
white subjects. Further research is needed to assess the
impact of traditional cardiovascular risk factors, comor-
bidities, psoriasis disease severity, and the choice of lipid-
lowering therapy on the trends in lipids in patients with
psoriasis. However, our subgroup analyses comparing
patients with and without psoriasis among subgroups of
patients with obesity and statin-users somewhat elucidate
these issues. We were unable to perform an analysis of
lipid trends by psoriasis disease severity score, as data on
the severity and extent of skin involvement were not con-
sistently available in this retrospective study. In addition,
temporary changes in lipids due to acute illness are pos-
sible, and we were unable to exclude such lipid measure-
ments from our analyses. However, acute illness is
relatively rare and measurement of lipids are unlikely to
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therefore, this issue should have little impact on or results.
Conclusions
Patients with psoriasis had a significant decrease in TC
and LDL levels during the 5 years before psoriasis inci-
dence but the magnitude of the reduction was smaller
than that seen in non-psoriasis subjects. Although there
was no difference in the trends of TG and HDL levels
between the two cohorts, mean TG levels were signifi-
cantly higher in psoriasis subjects compared with non-
psoriasis subjects. HDL levels were significantly lower in
patients with psoriasis compared with non-psoriasis sub-
jects. Lipid trends were otherwise similar in psoriasis
and non-psoriasis cohorts during the 5 years after psor-
iasis incidence/index date. These changes are unlikely to
be caused by lipid lowering treatment alone. The cause
and implications of the apparent changes in lipid profile
before psoriasis incidence require further exploration.
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